The case for & against
Bull & Bear analysis
Bullish
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is a biopharmaceutical company focused on developing innovative therapies for autoimmune diseases, particularly targeting lupus nephritis with its lead product, Lupkinis (voclosporin). The company is strategically positioned in the autoimmune treatment market and is gaining traction with its pipeline products, particularly the dual APRIL inhibitors, as part of the transition towards more effective treatment paradigms. Aurinia operates within the rapidly growing autoimmune market, driven by increased diagnosis rates and evolving treatment guidelines.
Bull says
- ↑Q4 2025 revenue of $77.1M, up 29% YoY
- ↑2026 net product sales expected $305M–$315M (+12%–16%)
- ↑Lupkinis added to ACR guidelines; >50% prescriptions from rheumatologists
- ↑Q4 cash flow $45.7M, +52% YoY; gross margin 91%
- ↑Repurchased 12.2M shares for $98.2M in 2025
- ↑High earnings yield, strong profitability, positive momentum, low leverage
Bear says
- ↓Exclusivity ends January 2026; generic entrants threaten market share
- ↓No dividend yield risks investor confidence in downturns
- ↓Short interest elevated; could amplify stock volatility
- ↓Book-to-price suggests overvaluation relative to peers
- ↓Growth hinges on physician adoption; behavior change may lag
- ↓Small market cap and negative size factor may limit growth
Earnings Call · Q4 2024 · Mgmt. Guidance
Updated 07-14-2026bullish
Transcript signals
Bull points
- For the fourth quarter of 2024, total revenue was $59.9 million, up 33% from $45.1 million in the same period of 2023.
- For the full year 2024, total revenue was $235.1 million, up 34% from $175.5 million in 2023.
- For the fourth quarter of 2024, net product sales of Flukinus were $57.6 million, up 36%, compared to $42.3 million in the same period of 2023.
Bear points
- For the year ended December 31, 2024, gross margin was 88% compared to 92% in 2023.
- decrease in both pre-arrays is primarily due to lower personnel costs, including share-based compensation and overhead costs, as a result of our strategic restructuring efforts in 2024, coupled with a reduction in non-personnel R&D expenses as a result of ceasing development of the company's AUR 300 development program.
- our guidance range is, as we said on the call, very much driven by what we know now after being in our fifth year on the market. And looking very closely at our historical financial results and using that to sort of project out where we see the year. As you may see, obviously, the low end of that projection is, you know, sort of flattish to slightly up versus where we were in Q4.
Read full transcript analysis ›